Company intelligence / Profile preview

Vedicinals

Pune, Maharashtra, Indiavedicinals.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Clinical trials showed Vedicinals9 improved outcomes in COVID-19 patients, including faster viral clearance, accelerated lung damage repair, prevention of severe disease progression, improvements in biomarkers (IL-6, CRP), faster symptom resolution, and organ protection. Recent research (February 2025) demonstrated Vedicinals9 Advanced's ability to mitigate LPS-induced inflammation and oxidative stress in RAW264.7 mouse macrophages, showing anti-inflammatory and antioxidant properties.[3][5][6]

Therapeutic areas: PulmonologyImmunologyInfectious Diseases
Modalities: NutraceuticalsPolyherbal formulations
Industry: Food & Nutrition

Drug pipeline

1 asset

Vedicinals9

Commercial

Indications: COVID-19, Lung cancer

Partnerships

Tirupati Life SciencesEthix Pharma

Beyond the preview

Go deeper on Vedicinals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vedicinals.

Explore the full profile